Global Market Report

Global Pulmonary Arterial Hypertension Market Report 2019-2029

Increasing prevalence of Pulmonary Arterial Hypertension (PAH) and government support for the development of orphan drugs are fueling the growth.

SKU: PHA0435 Category: Tag: Code: PHA0435Pages: 165
Clear
← Back to category Therapeutic Drugs

Description

Market Definition:
• Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension (PH) condition, which means high blood pressure in the lungs. Many diseases such as obstructive sleep apnea (OSA), lung diseases, diastolic heart failure and diseases of the left heart can cause the pressures in the pulmonary arteries to elevate but is not pulmonary arterial hypertension.
• PAH is a life threatening disease characterized by an increase in pulmonary vascular resistance that eventually leads to death. It is a rare disease, affects about 15-70 people per million in the U.S. The symptoms of PAH are difficult to diagnose as the symptoms are common to other diseases

Market Overview and Trends
• The United States is the main contributor to the PAH market with the development of new therapies and increasing cases of pulmonary arterial hypertension. The U.S. has great potential in the years ahead with rising awareness about treatment options of PAH
• Due to huge population base, rapid economic developments, and improving healthcare systems are major driving factors for market growth in APAC region.

Market Dynamics:

Factors Influencing the Market Growth:
• Increasing prevalence of Pulmonary Arterial Hypertension (PAH) and government support for the development of orphan drugs are fueling the growth
• The occurrence of this disorder has intensified due to the risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Presence of a large geriatric population, with lower levels of immunity and prone to PAH and associated diseases, is a high impact-rendering driver for the PAH market
• Government initiatives, such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are also anticipated to support market growth.

Factors Restraining the Market Growth:
• Patent expiration, high cost and lack of awareness are few factors which are likely to hinder the industry growth over the forecast timeframe.

Market Segmentation 2019-2029:
The pulmonary arterial hypertension market is segmented on the mode of administration, drug class, and geography.

Mode of Administration
• Oral Administration Market, 2019-2029
• Injectables Market, 2019-2029
• Inhalation Market, 2019-2029

Drug Class
• Prostacyclin & Prostacyclin Analogs Market, 2019-2029
• Soluble Guanylate Cyclase (SGC) Stimulators Market, 2019-2029
• Endothelin Receptor Antagonists (ERA) Market, 2019-2029
• Phosphodiesterase 5 (PDE-5) Market, 2019-2029

Geographic Breakdown
Focused regional forecasts and analysis explore the future opportunities:
• North America Market, 2019-2029
• Europe Market, 2019-2029
• Asia-Pacific Market, 2019-2029
• LAMEA Market, 2019-2029

Competitive Analysis:
• Research and development are the primary strategy adopted by the key players in the Pulmonary arterial hypertension market.
• These companies have developed various strategies and developments such as product launch, partnerships, mergers & acquisitions, joint venture, and collaborations.
• The market is consolidated and competitive in nature. Companies enjoy the benefit of barrier in the entry to other firms due to high price interdependency.

Major Market Players:
GlaxoSmithKline Plc.; Actelion Pharmaceuticals, Ltd.; United Therapeutics Corporation; Pfizer, Inc.; Gilead Sciences, Inc., Johnson & Johnson, DAIICHI SANKYO, and Novartis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Stakeholders


2. Research Methodology
2.1 Research Data
2.1.1 Primary Data
2.1.2 Secondary Data
2.2 Market Size Estimation
2.3 Research Assumptions
3. Executive Summary


4. Industry Insights


5. Global Pulmonary Arterial Hypertension Market - By Mode of Administration
5.1 Oral Administration
5.2 Injectables
5.3 Inhalation


6. Global Pulmonary Arterial Hypertension Market - By Drug Class
6.1 Prostacyclin & Prostacyclin Analogs
6.2 Soluble Guanylate Cyclase (SGC) Stimulators
6.3 Endothelin Receptor Antagonists (ERA)
6.4 Phosphodiesterase 5 (PDE-5)


7. Global Pulmonary Arterial Hypertension Market - By Geography
7.1 North America
7.1.1 US
7.1.2 Canada
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 UK
7.2.4 Rest of Europe
7.3 Asia-Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Rest of APAC
7.4 LAMEA
7.4.1 Latin America
7.4.2 Middle East
7.4.3 Africa


8. Competitive Landscape


9. Company Profiles
9.1 GlaxoSmithKline Plc.
9.2 Actelion Pharmaceuticals, Ltd.
9.3 United Therapeutics Corporation
9.4 Pfizer, Inc.
9.5 Gilead Sciences, Inc.
9.6 Johnson & Johnson
9.7 DAIICHI SANKYO
9.8 Novartis
9.9 Other Players


10. Appendix


List of Tables
Table 1 Global Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 2 Global Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 3 Global Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Region, (US$ Mn AGR%, CAGR%), 2019-2029
Table 4 North America Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 5 North America Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 6 U.S. Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 7 U.S. Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 8 Canada Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 9 Canada Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 10 Europe Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 11 Europe Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 12 Germany Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 13 Germany Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 14 France Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 15 France Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 16 UK Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 17 UK Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 18 Rest of Europe Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 19 Rest of Europe Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 20 Asia-Pacific Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 21 Asia-Pacific Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 22 Japan Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 23 Japan Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 24 China Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 25 China Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 26 India Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 27 India Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 28 Rest of APAC Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 29 Rest of APAC Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 30 LAMEA Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 31 LAMEA Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 32 Latin America Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 33 Latin America Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 34 Middle East Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 35 Middle East Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029
Table 36 Africa Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Mode of Administration, (US$ Mn AGR%, CAGR%), 2019-2029
Table 37 Africa Pulmonary Arterial Hypertension Market Revenue Analysis & Forecast, By Drug Class, (US$ Mn AGR%, CAGR%), 2019-2029


List of Figures
Figure 1 Global Pulmonary Arterial Hypertension Market: Segmentation
Figure 2 Global Pulmonary Arterial Hypertension Market: Research Design
Figure 3 Global Pulmonary Arterial Hypertension Market: 3 Drivers, Restraints, Opportunities, and Challenges
Figure 4 Global Pulmonary Arterial Hypertension Market: By Mode of Administration
Figure 5 Global Pulmonary Arterial Hypertension Market: By Drug Class
Figure 6 Global Pulmonary Arterial Hypertension Market: By Region
Figure 7 North America Pulmonary Arterial Hypertension Market: Market Snapshot
Figure 8 Europe Pulmonary Arterial Hypertension Market: Market Snapshot
Figure 9 Asia-Pacific Pulmonary Arterial Hypertension Market: Market Snapshot
Figure 10 LAMEA Pulmonary Arterial Hypertension Market: Market Snapshot
Figure 11 Market Share/Ranking : Financial Snapshot
Figure 12 GlaxoSmithKline Plc. : Financial Snapshot
Figure 13 Actelion Pharmaceuticals, Ltd. : Financial Snapshot
Figure 14 United Therapeutics Corporation : Financial Snapshot
Figure 15 Pfizer, Inc. : Financial Snapshot
Figure 16 Gilead Sciences, Inc. : Financial Snapshot
Figure 17 Johnson & Johnson : Financial Snapshot
Figure 18 DAIICHI SANKYO : Financial Snapshot
Figure 19 Novartis : Financial Snapshot
Figure 20 Other Players : Financial Snapshot

Actelion Pharmaceuticals, Ltd.
DAIICHI SANKYO
Gilead Sciences, Inc.
GlaxoSmithKline Plc.
Johnson & Johnson
Novartis
Pfizer, Inc.
United Therapeutics Corporation